参考文献/References:
[1].Lloyd-Jones D,Adams R,Carnethon M,et al. Heart disease and stroke statistics—2009 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J]. Circulation,2009,119(3):480-486.
[2].Zhu G,Cao L,Wu J,et al. Co-morbid intersections of cancer and cardiovascular disease and targets for natural drug action:reprogramming of lipid metabolism[J]. Biomed Pharmacother,2024,176:116875.
[3].Toldo S,Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases[J]. Nat Rev Cardiol,2024,21(4):219-237.
[4].Stanley WC,Recchia FA,Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart[J]. Physiol Rev,2005,85(3):1093-129.
[5].Miklas JW,Clark E,Levy S,et al. TFPa/HADHA is required for fatty acid beta-oxidation and cardiolipin re-modeling in human cardiomyocytes[J]. Nat Commun,2019,10(1):4671.
[6].Liu X,Zhang Y,Deng Y,et al. Mitochondrial protein hyperacetylation underpins heart failure with preserved ejection fraction in mice[J]. J Mol Cell Cardiol,2022,165:76-85.
[7].Benador IY,Veliova M,Liesa M,et al. Mitochondria bound to lipid droplets:where mitochondrial dynamics regulate lipid storage and utilization[J]. Cell Metab,2019,29(4):827-835.
[8].Wai T,Langer T. Mitochondrial dynamics and metabolic regulation[J]. Trends Endocrinol Metab,2016,27(2):105-117.
[9].Pan A,Sun XM,Huang FQ,et al.The mitochondrial β-oxidation enzyme HADHA restrains hepatic glucagon response by promoting β-hydroxybutyrate production[J]. Nat Commun,2022,13(1):386.
[10].Qin C,Gong S,Liang T,et al. HADHA regulates respiratory complex assembly and couples FAO and OXPHOS[J]. Adv Sci (Weinh) ,2024,11(47):e2405147.
[11].Menzies KJ,Zhang H,Katsyuba E,et al. Protein acetylation in metabolism—Metabolites and cofactors[J]. Nat Rev Endocrinol,2016,12(1):43-60.
[12].Verdin E,Ott M. 50 years of protein acetylation:from gene regulation to epigenetics,metabolism and beyond[J]. Nat Rev Mol Cell Biol,2015,16(4):258-264.
[13].Thapa D,Wu K,Stoner MW,et al.The protein acetylase GCN5L1 modulates hepatic fatty acid oxidation activity via acetylation of the mitochondrial β-oxidation enzyme HADHA[J]. J Biol Chem,2018,293(46):17676-17684.
[14].Deng Y,Liu X,Xie M,et al. Obesity Enables NLRP3 activation and induces myocardial fibrosis via hyperacetylation of HADHa[J]. Diabetes,2023,72(11):1597-1608.
[15].Shvedunova M,Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation[J]. Nat Rev Mol Cell Biol,2022,23(5):329-349.
[16].Lundby A,Lage K,Weinert BT,et al. Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns[J]. Cell Rep,2012,2(2):419-431.
[17].Hansen BK,Gupta R,Baldus L,et al. Analysis of human acetylation stoichiometry defines mechanistic constraints on protein regulation[J]. Nat Commun,2019,10(1):1055.
[18].Aka JA,Kim GW,Yang XJ. K-acetylation and its enzymes:overview and new developments[J]. Handb Exp Pharmacol,2011,206:1-12.
[19].Ritterhoff J,Tian R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy:new paradigms and challenges[J]. Nat Rev Cardiol,2023,20(12):812-829.
[20].Lopaschuk GD,Ussher JR,Folmes CD,et al. Myocardial fatty acid metabolism in health and disease[J]. Physiol Rev,2010,90(1):207-258.
[21].Charidemou E,Kirmizis A. A two-way relationship between histone acetylation and metabolism[J]. Trends Biochem Sci,2024,49(12):1046-1062.
[22].Campisi J. Senescent cells,tumor suppression,and organismal aging:good citizens,bad neighbors[J]. Cell,2005,120(4):513-522.
[23].Ho TCS,Chan AHY,Ganesan A. Thirty years of HDAC inhibitors:2020 insight and hindsight[J]. J Med Chem,2020,63(21):12460-12484.
[24].Chi Z,Chen S,Xu T,et al. Histone deacetylase 3 couples mitochondria to drive IL-1β-dependent inflammation by configuring fatty acid oxidation[J]. Mol Cell,2020,80(1):43-58.e7.
[25].Wu QJ,Zhang TN,Chen HH,et al. The sirtuin family in health and disease[J]. Signal Transduct Target Ther,2022,7(1):402.
[26].Diao Z,Ji Q,Wu Z,et al. SIRT3 consolidates heterochromatin and counteracts senescence[J]. Nucleic Acids Res,2021,49(8):4203-4219.
[27].Lombard DB,Alt FW,Cheng HL,et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation[J]. Mol Cell Biol,2007,27(24):8807-8814.
[28].Hirschey MD,Shimazu T,Goetzman E,et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation[J]. Nature,2010,464(7285):121-125.
[29].Scott I,Webster BR,Li JH,et al. Identification of a molecular component of the mitochondrial acetyltransferase programme:a novel role for GCN5L1[J]. Biochem J,2012,443(3):655-661.
[30].Scott I,Webster BR,Chan CK,et al. GCN5-like protein 1 (GCN5L1) controls mitochondrial content through coordinated regulation of mitochondrial biogenesis and mitophagy[J]. J Biol Chem,2014,289(5):2864-2872.
[31].Thapa D,Zhang M,Manning JR et al. Acetylation of mitochondrial proteins by GCN5L1 promotes enhanced fatty acid oxidation in the heart[J]. Am J Physiol Heart Circ Physiol,2017,313(2):H265-H274.
[32].Pougovkina O,te Brinke H,Ofman R et al. Mitochondrial protein acetylation is driven by acetyl-CoA from fatty acid oxidation[J]. Hum Mol Genet,2014,23(13):3513-3522.
[33].Libby P,Mallat Z,Weyand C. Immune and inflammatory mechanisms mediate cardiovascular diseases from head to toe[J]. Cardiovasc Res,2021,117(13):2503-2505.
[34].Davis BK,Wen H,Ting JP. The inflammasome NLRs in immunity,inflammation,and associated diseases[J]. Annu Rev Immunol,2011,29:707-735.
[35].He Y,Hara H,Nú?ez G. Mechanism and regulation of NLRP3 inflammasome activation[J]. Trends Biochem Sci,2016,41(12):1012-1021.
[36].Sokolova M,Sjaastad I,Louwe MC,et al. NLRP3 inflammasome promotes myocardial remodeling during diet-induced obesity[J]. Front Immunol,2019,10:1621.
[37].Sandanger ?,Ranheim T,Vinge LE,et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury[J]. Cardiovasc Res,2013,99(1):164-174.
[38].Catapano AL,Pirillo A,Norata GD. Vascular inflammation and low-density lipoproteins:is cholesterol the link? A lesson from the clinical trials[J]. Br J Pharmacol,2017,174(22):3973-3985.
[39].Maffia P,Cirino G. Targeting inflammation to reduce cardiovascular disease risk[J]. Br J Pharmacol,2017,174(22):3895-3897.
[40].Mouton AJ,Li X,Hall ME,et al. Obesity,hypertension,and cardiac dysfunction:novel roles of immunometabolism in macrophage activation and inflammation[J]. Circ Res,2020,126(6):789-806.
[41].Horton JL,Martin OJ,Lai L,et al. Mitochondrial protein hyperacetylation in the failing heart[J]. JCI Insight,2016,2(1):e84897.